New daily pill aims to tame stubborn seizures in tuberous sclerosis

NCT ID NCT07680322

Not yet recruiting Disease control Sponsor: Aeovian Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests an oral drug, AV078, in people aged 12 and older with tuberous sclerosis complex (TSC) whose seizures are not controlled by standard medications. Participants are randomly assigned to receive AV078 or a placebo for 12 weeks. The goal is to see if AV078 safely reduces seizure frequency and improves overall symptoms of TSC.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AV078
What this could lead to: If it works, AV078 could offer a new daily pill to reduce hard-to-control seizures in people with tuberous sclerosis complex.
What could go wrong: This is an early Phase 2 trial with only 42 participants. The drug may not reduce seizures more than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Resistant Epilepsy epilepsy tuberous sclerosis tuberous sclerosis 1 visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY TUBEROUS SCLEROSIS COMPLEX

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.